Israel’s MediWound has commenced a Phase 3 study to valuate the efficacy and safety of its innovative NexoBrid treatment for severe burns in children.  The study plans to be conducted in around 25 sites in Europe and Israel.  NexoBrid removes dead or damaged skin without harming viable tissue.

http://ir.mediwound.com/releasedetail.cfm?ReleaseID=879786